Real-world efficacy of MiniMed™780G recommended settings (glycemic target 100 mg/dL, active insulin time 2 hours) in youth and young adults with type 1 diabetes
Switching to the recommended MiniMed™780G settings, driven primarily by AIT reduction in most patients, was safe and effective, improving glycemic control without increasing hypoglycemia. These findings support broader use of these settings in pediatric and young adult patient with type 1 diabetes.
Authors
- Mohamad Maghnie (ORCID: https://orcid.org/0000-0002-7183-5238)
- Marta Bassi (ORCID: https://orcid.org/0000-0002-9166-1079)
- Nicola Minuto (ORCID: https://orcid.org/0000-0002-5280-6319)
- Giordano Spacco (ORCID: https://orcid.org/0009-0001-9889-5409)
- Maria Grazia Calevo (ORCID: https://orcid.org/0000-0002-6246-9299)
- Margherita Di Jorgi
- Andrea Pintabona
- G Siri
- Federico Pezzotta (ORCID: https://orcid.org/0009-0009-5022-2027)
Institutions
- Istituto Giannina Gaslini (IT)
- University of Genoa (IT)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-09-12
- DOI
- https://doi.org/10.3389/fendo.2025.1670266
- Citations
- 3
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.88